Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
accuracy, ADC, advice, advisor, Assuramed, broaden, California, Cellnovo, Central, Coproration, Daniel, Debiotech, deficiency, driven, feasibility, immaterial, jurisdiction, Levangie, Lortz, Medisize, occlusive, platform, preexisting, prepaid, Puerto, release, reorder, repatriate, Rico, Singapore, team, unremitted, unspecific, vascular
Removed:
adjunct, afforded, Australia, billed, bundle, Calibra, channel, delivered, denied, derived, designing, devoted, dexcom, display, Eastern, eleven, extinguishment, glucagon, implemented, Jaffe, labeled, launched, multi, penalty, Plastic, reach, receiver, resolving, Sensile, Starbridge, Starter, substantive, substitute, sue, suit, taxing
Filing tables
Filing exhibits
Related press release
PODD similar filings
Filing view
External links
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements (Forms S-3 No. 333-158354, 333-158353, 333-174746, 333-172782 and 333-175067, Forms S-8 No. 333-144636, 333-153176, 333-183166 and 333-164883) of Insulet Corporation and in the related Prospectus of our reports dated February 28, 2013, with respect to the consolidated financial statements and schedule of Insulet Corporation, and the effectiveness of internal control over financial reporting of Insulet Corporation, included in this Annual Report (Form 10-K) for the year ended December 31, 2012.
/s/ Ernst & Young LLP
Boston, Massachusetts
February 28, 2013